Myc Inhibitor OMO-103
Phase 1Small molecule
Myc Inhibitor OMO-103 is one of 7 small molecule programs targeting Locally Advanced Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Locally Advanced Pancreatic Ductal Adenocarcinoma
#DrugCompanyPhaseTrials
1Cotellic
RochePhase 1
Lynparza
AstraZenecaPhase 1
Imjudo
AstraZenecaPhase 1
Saruparib
AstraZenecaPhase 1
Onvansertib
CCardiff Oncology
Phase 1
Azenosertib
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1
Myc Inhibitor OMO-103
OOHSU Knight Cancer Institute
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Myc Inhibitor OMO-103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- OOHSU Knight Cancer Institute